Push To Fast Track Drug To Help Children With Deadly Disorder

Posted: Published on March 21st, 2014

This post was added by Dr Simmons

By Jennifer Jarrell Thursday March 20, 2014 11:37 PM UPDATED: Friday March 21, 2014 12:48 AM COLUMBUS, Ohio -

It's a deadly disease without a cure, but researchers say they have a drug that slows the progression.

Now, families of boys with a rare form of muscular dystrophy are pushing for government approval.

7-year-old Jackson Maynard can play football with his big brother right now, but he likely won't be able to in a few years.

"He's starting to fall a lot at school, and he has difficulty getting up and down the steps," Jackson's mother, Kelly Maynard, said.

Maynard said her son was diagnosed with Duchenne Muscular Dystrophy two years ago. She said her little boy is losing strength every day.

"Boys are usually in a wheelchair by the time they are 10 or 12. It is a 100% fatal disease, most boys don't live past their 20s with this disease," Maynard said. Researchers, including a doctor from Nationwide Children's Hospital in Columbus, recently went to Washington to testify on behalf of the drug Eteplirsen. Dr. Jerry Mendell said the drug works.

Maynard isn't able to give the drug to her son because it still hasn't been approved by the Food and Drug Administration. In an effort to change that, she is pushing a petition to get the FDA to accelerate approval for Eteplirsen.

Maynard said the goal is to get 100,000 signatures by March 29. She said only then will the White House comment as to why the FDA isn't moving faster.

In a letter from the agency's drug information director, Catherine Chew, she explains the FDA has reached no conclusions about the possibility of using accelerated approval for any new drug for the treatment of Duchenne Muscular Dystrophy. Maynard says she fears approval may be years away.

Continue reading here:
Push To Fast Track Drug To Help Children With Deadly Disorder

Related Posts
This entry was posted in Muscular Dystrophy Treatment. Bookmark the permalink.

Comments are closed.